Overview

Gout Therapeutic Market is estimated to value over CAGR of over 8% during the forecast period 2022 to 2028

Growing adoption of biologics such as Rilonacept, Canakinumab and Krystexxa have been launched in the market and the expansion in the adoption of these biologics, owing to their ability to create strong anti-inflammatory action is registered to boost the market value during the forecast time frame. In addition, a number of other drugs that are undergoing clinical trials are projected to augment the gout therapeutic market growth.

Research analysis has shown that the volume of gout has showcased significant growth in recent years. It is primarily attributed to untreated or uncontrolled metabolic disorder and exceedingly high levels of uric acid present in the body. North America is registered to have a heightened gout market due to lifestyle-related problems such as obesity, high intake of alcohol and even inflammatory illnesses. Measures have been undertaken by various nations to raise awareness regarding chronic diseases and how biologics has contributed to the treatment of gout in the populations. In fact, the acceptance of new treatments and a better awareness regarding arthritic and chronic conditions, will most likely propel the market growth.

Recommendations of various medications and therapies are given to the patients and the medications are prescribed according to the severity of the ailment. Numerous companies have boosted their investments in research and development to give way for new and improved innovations in medication.

Based on the segmentation of components, the drug type in the market for gout therapeutics has been categorized into biologics, colchicine, NSAIDS, antihyperuricemic agents (also known as urate-lowering drugs) and corticosteroids. Biologics has seen a rise in adoption and are an alternative to corticosteroids and NSAIDS, as they culminate in far more effective results. It is for this reason that the biologics segment is expected to grow and in all likelihood, gain sizable gout therapeutic market share during the forecast time frame.

Antihyperuricemic agents which are also known as urate-lowering drugs, are usually recommended as the first phase of treatment. Furthermore, the acceptance and subsequent success Target 2 Treat, entails integrating both biologic as well as synthetic urate-lowering drugs. Extensive usage of these drugs in treating gout disease have contributed to the market shares in antihyperuricemic agents and biologic segments.

In terms of the distribution channel, the market for gout therapeutics has been fragmented into online, retail and hospital pharmacies. In recent years, the segment for retail pharmacy has witnessed large shares in the market on a scale.

Major players who are controlling this market includes Teijin Pharma Limited, Horizon Pharma plc, Novartis AG, Merck & Co. Inc., Ironwood Pharmaceuticals, Inc., Grunenthal Group, JW Pharmaceutical, Takeda Pharmaceutical Company Limited, Selecta Biosciences, Inc., AstraZeneca, Regeneron Pharmaceuticals, Inc.

Gout Therapeutic Market Segmentation:

By Disease Condition

Acute Gout
Chronic Gout

By Drug Class

Colchicine
Antihyperuricemic agents (Urate-Lowering Drugs)
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Corticosteroids
Biologic Response Modifiers (Biologics)

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Region

Europe
North America
Asia Pacific
Latin America
Middle East & Africa

FutureWise Key Takeaways:

Growth prospects
SWOT analysis
Key trends
Key data-points affecting market growth

Objectives of the Study:

To provide with an exhaustive analysis on the market by disease condition, by drug class, by distribution channel, and by region
To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
To evaluate and forecast micro-markets and the overall market
To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East & Africa
To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

•   We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
•   The customization Mobility Care offered are free of charge with purchase of any license of the report
•   You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com